Oculis Holding AG
NASDAQ:OCS
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CH |
O
|
Oculis Holding AG
NASDAQ:OCS
|
1.5B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
934.5B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
257.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
223.5B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
233.6B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
285.6B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.3B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Oculis Holding AG
Glance View
Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improve eye care. The company is headquartered in Zug, Zug and currently employs 28 full-time employees. The firm is focused on the development of eye disease treatment for ophthalmology. The company includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The firm have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
